These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37335203)

  • 21. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comparative Study of Aripiprazole, Olanzapine, and L-Methylfolate Augmentation in Treatment Resistant Obsessive-Compulsive Disorder.
    Dar SA; Wani RA; Haq I
    Psychiatr Q; 2021 Dec; 92(4):1413-1424. PubMed ID: 33830427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
    Pessina E; Albert U; Bogetto F; Maina G
    Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
    Wheaton MG; Rosenfield D; Foa EB; Simpson HB
    J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Bruno A; Micò U; Pandolfo G; Mallamace D; Abenavoli E; Di Nardo F; D'Arrigo C; Spina E; Zoccali RA; Muscatello MR
    J Psychopharmacol; 2012 Nov; 26(11):1456-62. PubMed ID: 22351381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
    Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
    J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder.
    Di Salvo G; Maina G; Pessina E; Teobaldi E; Barbaro F; Martini A; Albert U; Rosso G
    Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33374357
    [No Abstract]   [Full Text] [Related]  

  • 31. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):375-80. PubMed ID: 24406025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Hollander E; Baldini Rossi N; Sood E; Pallanti S
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):397-401. PubMed ID: 14604454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Aboujaoude E; Barry JJ; Gamel N
    J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials.
    Suhas S; Malo PK; Kumar V; Issac TG; Chithra NK; Bhaskarapillai B; Reddy YCJ; Rao NP
    World J Biol Psychiatry; 2023 Feb; 24(2):162-177. PubMed ID: 35615998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Fortschr Neurol Psychiatr; 2011 Aug; 79(8):453-66. PubMed ID: 21809258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
    Pfanner C; Marazziti D; Dell'Osso L; Presta S; Gemignani A; Milanfranchi A; Cassano GB
    Int Clin Psychopharmacol; 2000 Sep; 15(5):297-301. PubMed ID: 10993132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation strategies in obsessive-compulsive disorder.
    Arumugham SS; Reddy JY
    Expert Rev Neurother; 2013 Feb; 13(2):187-202; quiz 203. PubMed ID: 23368806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
    McLean CP; Zandberg LJ; Van Meter PE; Carpenter JK; Simpson HB; Foa EB
    J Clin Psychiatry; 2015 Dec; 76(12):1653-7. PubMed ID: 26613263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.